SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition

The following table presents a summary of the activity in the Company’s contract liabilities pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the year ended December 31, 2023 (in thousands):


Opening balance, December 31, 2022 (As Restated)	$	35,139
Payments received in advance	1,755
Payments receivable	1,488
Revenue from performance obligations satisfied during reporting period	(9,042)
Closing balance, December 31, 2023	$	29,340

Current portion of contract liabilities	$	25,095
Long-term portion of contract liabilities	4,245
Total contract liabilities, December 31, 2023	$	29,340

The following table presents our collaboration revenue disaggregated by collaborator and timing of revenue recognition (in thousands):


	Year Ended December 31, 2023
	Mundipharma		Janssen		Melinta
Revenue from Collaboration and License Agreements:
Point in Time:

License of Intellectual Property - upon milestones achieved	$	3,252	$	2,347	$	17,257
Clinical Drug Supply	26		—		—
Royalties	—		—		168
Over Time:
Research and Development Services	12,303		19,011		2,441
Clinical Supply Services	840		1,925		—
Total Revenue from Collaboration and License Agreements	$	16,421	$	23,283	$	19,866


	Year Ended December 31, 2022
	Mundipharma		Janssen		Melinta
			(As Restated)
Revenue from Collaboration and License Agreements:
Point in Time:
License of Intellectual Property - upon transfer of license	$	—	$	—	$	25,885
License of Intellectual Property - upon milestones achieved	3,252		976		—
Clinical Drug Supply	484		—		—

Over Time:
Research and Development Services	9,595		18,814		811
Clinical Supply Services	925		3,706		—
Total Revenue from Collaboration and License Agreements	$	14,256	$	23,496	$	26,696